Circulating white blood cell count and measures of adipose tissue inflammation predict higher 24-h energy expenditure

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 275-280

  He, Jianying ^a   Le, Duc Son ^a   Xu, Xiaoyuan ^b   Scalise, Michael ^b   Ferrante, Anthony W ^b   Krakoff, Jonathan ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL SUBCUTANEOUS FAT; ADOLESCENT; ADULT; AMERICAN INDIAN; ARTICLE; CHRONIC INFLAMMATION; ENERGY EXPENDITURE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; OBESITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; HUMANS; INDIANS, NORTH AMERICAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUBCUTANEOUS FAT; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 75149150903     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0831     Document Type: Article

References (31)

1. Hotamisligil GS, Arner P, Caro JF, Atkinson RL & Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation 1995 95 2409-2415.
2. Hotamisligil GS, Shargill NS & Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 259 87-91.
3. Grimble RF. Inflammatory status and insulin resistance. Current Opinion in Clinical Nutrition and Metabolic Care 2002 5 551-559.
4. Bouchard L, Mauriege P, Vohl MC, Bouchard C & Perusse L. Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005 12 136-143.
5. Argiles JM, Lopez-Soriano J, Busquets S & Lopez-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB Journal 1997 11 743-751.
6. Spiegelman BM & Hotamisligil GS. Through thick and thin: wasting, obesity, and TNF alpha. Cell 1993 73 625-627.
7. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A & Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987 50 555-563.
8. Xu H, Hirosumi J, Uysal KT, Guler AD & Hotamisligil GS. Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 2002 143 1502-1511.
9. Pannacciulli N, Bunt JC, Ortega E, Funahashi T, Salbe AD, Bogardus C & Krakoff J. Lower total fasting plasma adiponectin concentrations are associated with highermetabolic rates. Journal of Clinical Endocrinology and Metabolism 2006 91 1600-1603.
10. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ & Scherer PI. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. Journal of Clinical Investigation 2007 117 2621-2637.
11. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C & Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002 51 455-461.
12. Ravussin E, Lillioja S, Anderson TE, Christin L & Bogardus C. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. Journal of Clinical Investigation 1986 78 1568-1578.
13. Ortega Martinez de Victoria E, Xu X, Koska J, Francisco AM, Scalise M, Ferrante AW Jr & Krakoff J. Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes 2009 58 385-393.
14. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 2003 112 1796-1808.
15. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR & Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. American Journal of Physiology 1991 261 E457-E465.
16. Rothwell NJ. Cytokines and thermogenesis. International Journal of Obesity and Related Metabolic Disorders 1993 17 S98-S101.
17. Balkwill FR & Smyth JF. Interferons in cancer therapy: a reappraisal. Lancet 1987 2 317-319.
18. Evans DA, Jacobs DO & Wilmore DW. Tumor necrosis factor enhances glucose uptake by peripheral tissues. American Journal of Physiology 1989 257 R1182-R1189.
19. Marcora SM, Chester KR, Mittal G, Lemmey AB & Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. American Journal of Clinical Nutrition 2006 84 1463-1472.
20. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A & Chimenti S. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacological Research 2008 57 290-295.
21. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughman DE & Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004 53 336-346.
22. Amaral ME, Barbuio R, Milanski M, Romanatto T, Barbosa HC, Nadruz W, Bertolo MB, Boschero AC, Saad MJA, Franchini KG & Velloso LA. Tumor necrosis factor-alpha activates signal transduction in hypothalamus and modulates the expression of pro-inflammatory proteins and orexigenic/anorexigenic neurotransmitters. Journal of Neurochemistry 2006 98 203-212.
23. Saad MF, Alger SA, Zurlo F, Young JB, Bogardus C & Ravussin E. Ethnic differences in sympathetic nervous system-mediated energy expenditure. American Journal of Physiology 1991 261 E789-E794.
24. Young JB & Landsberg L. Diminished sympathetic nervous system activity in genetically obese (ob/ob) mouse. American Journal of Physiology 1983 245 E148-E154.
25. Tataranni PA, Young JB, Bogardus C & Ravussin E. A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Obesity Research 1997 5 341-347.
26. Sayk F, Vietheer A, Schaaf B, Wellhoener P, Weitz G, Lehnert H & Dodt C. Endotoxemia causes central downregulation of sympathetic vasomotor tone in healthy humans. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2008 295 R891-R898.
27. Diakakis GF, Parthenakis FI, Patrianakos AP, Koukouraki SI, Stathaki MI, Karkavitsas NS & Vardas PE. Myocardial sympathetic innervation in patients with impaired glucose tolerance: relationship to subclinical inflammation. Cardiovascular Pathology 2008 17 172-177.
28. Aso Y, Wakabayashi S, Nakano T, Yamamoto R, Takebayashi K & Inukai T. High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 2006 55 1014-1021.
29. Weyer C, Bogardus C & Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999 48 2197-2203.
30. Tarner IH, Muller-Ladner U, Uhlemann C & Lange U. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clinical Rheumatology 2008 28 397-402.
31. Rush EC, Plank LD & Yajnik CS. Interleukin-6, tumour necrosis factor-alpha and insulin relationships to body composition, metabolism and resting energy expenditure in a migrant Asian Indian population. Clinical Endocrinology 2007 66 684-690.